Skip to Main Content

Paper Details

In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
Pediatr Blood Cancer
2
2023
ALL, ALL PDXs, Acute lymphoblastic leukemia, B-lineage, B-lineage than T-lineage ALL PDXs, CD45, CD45 cells, Copiktra, Duvelisib, PDXs, PI3K, PI3K mRNA, PI3Ks, PIK3CD, PIK3CG, Phosphoinositide 3-kinases, cancer, children, chronic lymphocytic leukemia, duvelisib, hematological malignancies, huCD45, human, leukemia, leukemia cells, mice, mouse, patient, pediatric, pediatric ALL patient-derived xenografts, pediatric acute lymphoblastic leukemia, small lymphocytic lymphoma
Author NameAffiliation
Kathryn EvansChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Jonathan A PachterInc.
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Richard B LockChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
  • 1 - 5

Datasets

Release 1.2